NCT06990100 (DT4-EBMCA) is a NA clinical trial of ACL surgery in ACL Rupture, sponsored by SACIMEX.

Who is sponsoring NCT06990100?

NCT06990100 is sponsored by SACIMEX.

What drugs are being tested in NCT06990100?

Interventions in NCT06990100: ACL surgery.

What condition does NCT06990100 study?

NCT06990100 studies ACL Rupture.

Is NCT06990100 still recruiting?

NCT06990100 is currently completed. Last updated 25 May 2025.

Last reviewed 2025-05-25 · How we verify

NCT06990100: DT4-EBMCA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Performance and Safety of ENDOPACK® DT4-EBMCA in ACL Reconstruction 24 Months Post-surgery : Post-market Clinical Follow-up Study

Completed NA Last updated 25 May 2025

What this trial tests

NA trial testing ACL surgery in ACL Rupture in 36 participants. Completed in 12 May 2025.

Timeline

1 October 2024

Primary endpoint
1 April 2025

12 May 2025

Quick facts

Lead sponsor	SACIMEX
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	1 October 2024
Primary completion	1 April 2025
Estimated completion	12 May 2025
Sites	1 location across France

Drugs / interventions tested

ACL surgery

Conditions studied

ACL Rupture — all drugs for ACL Rupture →

Sponsor

SACIMEX

Who can join

18 and older, any sex, with ACL Rupture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anterior cruciate ligament (ACL) injuries are among the most common sports-related knee traumas. The DT4-EBMCA device, based on a quadrupled semitendinosus autograft technique, aims to provide effective and minimally invasive ligament reconstruction. This study evaluates its long-term performance and safety in routine clinical practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06990100 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SACIMEX
Last refreshed: 25 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06990100.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing